Light Sciences Oncology (Light)

Oncology Corporate Profile

HQ Location

12600 SE 38th Street, Suite 111
Bellevue, WA 98006

Company Description

Light Sciences (now LSO) was founded in 1994 to find and produce a commercially viable light-activated drug product to treat patients with solid tumor cancers.

Website: http://www.lsoncology.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Aptocine®light activated drug treatment1st line metastatic Colorectal cancerIII
Aptocine®light activated drug treatmentHepatocellular carcinoma (HCC)III
Aptocine®light activated drug treatmentGliomaII

View additional information on product candidates here »

Source: www.lsoncology.com

Recent News Headlines

New Data Presentations at SITC 2016 Annual Meeting Highlight Bristol-Myers Squibb’s Leadership in Advancing the Science of Immuno-Oncology Combinations

11/2/2016 11:12 am

(BMS) Nov 2, 2016 - Interim data evaluating the efficacy of lirilumab, an anti-KIR antibody, in combination with Opdivo (nivolumab), a PD-1 inhibitor, will be presented in a late-breaking oral session; late-breaking data from CheckMate -032 studying Opdivo plus Yervoy (ipilimumab) in metastatic urothelial carcinoma will also be presented.

OPEN Pre-Conference Highlights

10/20/2016 11:20 am

(ACCCBuzz) Oct 20, 2016 - We’re in St. Louis for the ACCC 33rd National Oncology Conference this week. Events got underway on Wednesday, October 19, with dynamic pre-conference sessions focused on some of the most challenging and rapidly evolving areas in cancer care delivery. Read on for highlights from the Oncology Pharmacy Education Network (OPEN) pre-conference.

Health Care Likely To Get Turn In Debate Spotlight

10/19/2016 11:43 am

(Politico/Politico Pulse) Oct 19, 2016 - Tonight's debate could be another prime-time moment for health care.

EU Green Light For Shire’s Pancreatic Cancer Drug Onivyde

10/19/2016 11:41 am

(PharmaTimes [UK]) Oct 19, 2016 - The European Medicines Agency has now issued a green light for Shire's pancreatic therapy Onivyde, following its US approval in July this year.

UV Light Robots Cut C. Diff Transmissions by 25 Percent on Cancer Patient Floors, Penn Study Finds

10/12/2016 11:34 am

(Penn Medicine) Oct 6, 2016 - Newly published research from Penn Medicine infection control specialists found that ultraviolet (UV) robots helped reduce the rates of transmission of the common bacterial infection known as Clostridium difficile (C. diff) among cancer inpatients – mostly blood cancer patients, a group more vulnerable to hospital-acquired infections – by 25 percent.

New Special Series in the Journal of Oncology Practice Highlights ASCO’s 2016 Quality Care Symposium

10/12/2016 11:32 am

(ASCO in Action) Oct 11, 2016 - The October print issue of the Journal of Oncology Practice (JOP) is a Special Series on ASCO’s 2016 Quality Care Symposium (QCS). The issue features research and highlights from the meeting that brought together top leaders in the field to share strategies and methods for measuring and improving the quality and safety of cancer care.

Astellas: Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care

10/11/2016 12:14 pm

(PharmiWeb.com) Oct 11, 2016 - Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve the cancer care experience for patients, caregivers and their loved ones – during the European Society of Medical Oncology (ESMO) Annual Congress in Copenhagen, Denmark Friday, October 7.

Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress

10/7/2016 11:00 am

(Yahoo! Finance) Oct 7, 2016 - Seattle Genetics, Inc. and Agensys, an affiliate of Astellas, today presented updated clinical data for enfortumab vedotin (ASG-22ME) and ASG-15ME at the European Society for Medical Oncology (ESMO) Congress being held October 7-11, 2016 in Copenhagen, Denmark.

Lilly Highlights Advancements in its Oncology Portfolio with New Data at ESMO 2016

10/5/2016 11:08 am

(Lilly) Oct 5, 2016 - Eli Lilly and Company will present data from several studies which further reinforce the advancement of its diverse clinical cancer portfolio during the European Society of Medical Oncology's (ESMO) 2016 Congress in Copenhagen, October 7-11.

Improved UN Database Spotlights Huge Global Disparities in Access to Cancer Care

9/29/2016 12:28 pm

(UN News Centre) Sept 28, 2016 - A revamped global database launched today by the United Nations atomic agency highlights startling disparities across the world when it comes to access to treatment and care for cancer.

New CancerLinQ™ Video Highlights Vanguard Practice Physicians Discussing Why They Chose to Join the Platform

9/19/2016 11:41 am

(ASCO in Action) Sept 16, 2016 - On September 16, ASCO released its most recent video about the CancerLinQ™ platform, the Society’s big data initiative to rapidly improve the quality of care for people with cancer.

2016 Symposium Highlights Notable Research Advances in Palliative Care

9/9/2016 10:49 am

(ASCO/2016 Palliative Care in Oncology Symposium) Sept 8, 2016 - Seven studies investigating key issues in palliative care will be presented at the 2016 Palliative Care in Oncology Symposium, taking place September 9-10, at the San Francisco Marriott Marquis.

New Articles Highlight the Potentials of Patient Reported Outcome Tools and Measurements

9/8/2016 11:26 am

(ASCO in Action) Sept 6, 2016 - Two studies on Patient Reported Outcome (PRO) measures from ASCO's 2016 Quality Care Symposium (QCS) are a part of an upcoming Journal of Oncology Practice QCS Specials Series.

Using Light to Control Genome Editing

8/26/2016 11:07 am

(MIT News) Aug 25, 2016 - New technique offers precise manipulation of when and where genes are targeted.

Featured Studies for 2016 Palliative Care in Oncology Symposium Shed Light on Relationship Between Early Palliative Care & Coping, the Cancer Caregiving Experience and Accessibility of Palliative Care Services

8/18/2016 11:26 am

(ASCO) Aug 17, 2016 - Co-sponsors of the 2016 Palliative Care in Oncology Symposium announced today four abstracts that will be highlighted for media.

Expert Highlights Numerous Benefits of Atezolizumab in Bladder Cancer

8/18/2016 11:24 am

(Targeted Oncology) Aug 17, 2016 - Atezolizumab (Tecentriq) proves to be non-toxic and shows major survival advantage in patients with metastatic urothelial bladder cancer, according to David Nanus, MD.

New Moffitt Cancer Center Study Highlights Importance of Regular Lung Cancer Screenings for Those at High Risk

8/18/2016 10:55 am

(Moffitt) Aug 18, 2016 - Lung cancer is the leading cause of cancer death for men and women. It is also one of the most complex cancers, both at the molecular level and through its clinical behavior. Screening is paramount as it helps physicians diagnose and treat the disease in its earliest stages.

Rare Blood Cancer Therapy Oncaspar Gets NICE Green Light

8/3/2016 10:52 am

(PMLiVE [UK]) Aug 1, 2016 - The National Institute for Health and Care Excellence (NICE) has recommended Baxalta's Oncaspar (pegaspargase), a treatment for a rare form of leukaemia, in final draft guidance.

Patch That Delivers Drug, Gene, And Light-Based Therapy To Tumor Sites Shows Promising Results

7/25/2016 11:00 am

(MIT News) July 25, 2016 - In a paper published today in the journal Nature Materials, researchers at MIT describe an adhesive patch that can stick to the colorectal tumor site, either before or after surgery, to deliver a triple-combination of drug, gene, and photo (light-based) therapy.

Study Sheds Light On True Risk For Pancreatic Cancer In Patients With Cysts

7/12/2016 10:15 am

(ASGE) July 11, 2016 - A look back at more than half a million patient records has established that patients with pancreatic cysts have a significantly higher overall risk of pancreatic cancer compared to those without such cysts, according to a study in the July issue of GIE: Gastrointestinal Endoscopy, the journal of the American Society for Gastrointestinal Endoscopy (ASGE).

Study Sheds Light On Role Of Mutations In Metastasized Cancer

7/6/2016 12:09 pm

(MIT News) July 5, 2016 - Researchers identify genes that mutate in endometrial cancer, create a family tree describing the evolutionary history of the disease.

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association

6/13/2016 12:00 pm

(The Business Journals) June 11, 2016 - Phase 1 clinical data featured in press program and oral presentation demonstrate 76 percent objective response rate, including a 41 percent complete remission rate, in newly diagnosed AML patients treated with 33A combination therapy; data support recently initiated phase 3 CASCADE study evaluating 33A in combination with hypomethylating agents in AML patients.

Novartis Highlights Long-Term Safety Data Of Revolade® In Adults With Chronic Immune Thrombocytopenia, A Rare Blood Disorder

6/10/2016 12:00 pm

(Novartis) June 10, 2016 - Novartis today announced data from the largest study of its kind confirming the long-term safety profile of Revolade (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenia (ITP), with data for up to 6 years in some patients (median exposure was 2.4 years).

Kite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress

6/8/2016 11:41 am

(4-traders) June 8, 2016 - Results from ZUMA-1 Phase 1 study of KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL); SCHOLAR-1, first meta-analysis of patient-level outcomes in chemorefractory DLBCL, an understudied patient population; results from study of anti-CD19 CAR T cells in advanced lymphoma patients, conducted in partnership with the National Cancer Institute.

Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting

6/7/2016 02:24 pm

(Onconova Therapeutics) June 6, 2016 - Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data relating to the mechanistic rationale for combining rigosertib with azacitidine at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois.

Researchers Achieve RNA Interference, In a Lighter Package

6/8/2012 11:01 am

(MIT) June 4, 2012 - Using a technique known as “nucleic acid origami,” chemical engineers have built tiny particles made out of DNA and RNA that can deliver snippets of RNA directly to tumors, turning off genes expressed in cancer cells.

California Voters Reject Raising Tobacco Tax

6/7/2012 11:04 am

(Reuters) June 7, 2012 - California voters narrowly rejected a ballot measure that would have added a $1 tax to a pack of cigarettes in the state's primary election Tuesday, an outcome observers attributed to a $47 million ad blitz by the tobacco industry.

Early Economic Evaluation Highlights the Potential Benefits of Biomarkers to Guide Usage of Anti-Angiogenic Therapy for Metastatic Colorectal Cancer Patients

6/4/2012 06:03 pm

(Bloomberg) June 4, 2012 - GE Healthcare today announced results of a unique partnership with Fred Hutchinson Cancer Research Center and the Center for Sustainable Health at Arizona State University. This partnership is directed at identifying areas in oncology where diagnostics could provide high value through reducing costs, while at the same time maintaining or improving patient outcomes.

Jennerex Presents JX-594 Clinical Data at 2012 American Society of Clinical Oncology Annual Meeting

6/4/2012 05:05 pm

(Yahoo! Finance) June 4, 2012 - Jennerex highlights phase 2b liver cancer trial as well as programs in colorectal cancer and multi-dose IV administration.

Studies Report Findings in Patient-Centered Care

6/4/2012 05:04 pm

(ASCO) June 4, 2012 - New studies highlighting findings that will lead to improvements in the patient experience and identifying potential risks for development of cancers in the future were released today at a press briefing at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Studies Highlight Advances in Personalized Cancer Medicine

6/4/2012 05:04 pm

(ASCO) June 4, 2012 - New studies highlighting the promise of individualized, precision medicine were released today at a press briefing at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).

In California, It's Big Tobacco vs Lance Armstrong

6/2/2012 05:05 pm

(San Jose Mercury News/Associated Press) June 1, 2012 - Fabled as a mecca for the health-conscious and fitness-obsessed, California is also one of only a few states that has not hiked its cigarette taxes in the last decade, meaning it is less expensive to light up in Los Angeles and San Francisco than in many other places in the country.

Cyclacel Presents New Phase 2 Data of Sapacitabine for MDS at ASCO Annual Meeting

6/2/2012 05:03 pm

(NASDAQ) June 1, 2012 - Results highlight sapacitabine's activity in MDS and potential role as second-line therapy after treatment failure of hypomethylating agents.

Medicare Spotlights Hospitals With Especially Costly Patients

5/10/2012 12:01 pm

(Kaiser Health News) May 9, 2012 - The government has identified hundreds of hospitals whose Medicare patients are incurring especially high bills, a first step toward using bonuses and penalties to encourage more efficient care.

Throat Cancer Patients Who Are Positive For the Human Papilloma Virus (HPV) Respond Better to Radiotherapy Alone Than HPV-Negative Patients

5/10/2012 11:04 am

(ESTRO) May 10, 2012 - New findings from a large Danish database of cancer patients suggest that, even though the human papilloma virus (HPV) can trigger throat cancer, patients who are HPV-positive and are light smokers, or don’t smoke at all, have a good response to treatment using radiotherapy alone, without the addition of chemotherapy with its consequent toxic side-effects.

CMS Delays Sunshine Act Data Collection Until 2013

5/7/2012 12:00 pm

(Kaiser Health News) May 7, 2012 - Implementation of this provision of the health law, which is designed to shed light on the financial arrangements between doctors, drug makers and medical device companies, will now begin in 2013.

New Data Improve Understanding of Breast Cancer's Multiple Varieties

5/3/2012 12:00 pm

(ESMO) May 3, 2012 - New findings presented at Europe’s leading breast cancer translational research conference this year shed new light on the many biological differences between individual breast cancers.

Personalized Cancer Care Highlighted

4/27/2012 11:04 am

(Vanderbilt-Ingram Cancer Center) Apr 26, 2012 - The future of omics and personalized cancer medicine was in the spotlight as Vanderbilt University School of Medicine hosted a regional meeting of the Institute of Medicine (IOM) of the National Academies.

Acupuncture Is Equally Effective with Simulated Needles

3/28/2011 12:05 pm

(Karolinska Institutet) Mar 24, 2011 - Simulated acupuncture - sometimes referred to as placebo - is just as beneficial as real acupuncture for treating nausea in cancer patients undergoing radiotherapy, according to a study from Karolinska Institutet and Linköping University in Sweden.

Investor Pool Loses Majority Control of Roche

3/25/2011 12:03 pm

(Wall Street Journal) Mar 25, 2011 - The Swiss family that has controlled drug giant Roche Holding AG for decades said one family member has dropped out of the group's voting pool, meaning that the family pool has lost majority voting control of the company.

Combined Interventions Improve Depression In Cancer Patients

3/22/2011 12:05 pm

(OSUCCC-James) Mar 22, 2011 - A novel psychological treatment for depressed patients coping with the stresses of cancer significantly improved their depressive symptoms, while also improving fatigue and mental health quality of life.

Radical Surgery Removes Half of Pelvis, Saves Leg

3/22/2011 12:05 pm

(UC San Diego) Mar 21, 2011 - During a radical surgery to treat a rare bone cancer, surgeons at UC San Diego Health System and Moores Cancer Center removed 50 percent of a patient’s pelvis.

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott

3/22/2011 12:05 pm

(Seattle Genetics) Mar 22, 2011 - Seattle Genetics, Inc. today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.

Quest Diagnostics Paying $8/Shr for Gene Testing Co Celera

3/18/2011 11:05 am

(IB Times) Mar 18, 2011 - Quest Diagnostics Inc. announced an agreement to acquire smaller rival Celera Corp., a maker of diagnostic tests, for $8 per share to gain immediate access to genetic tests and pipeline of biomarkers.

Letters: There Is Medical Cost Shifting, but Not What You Think

3/17/2011 01:00 pm

(Wall Street Journal) Mar 17, 2011 - John F. Cogan, R. Glenn Hubbard and Daniel Kessler have it completely wrong on the "cost shifting" of health care from the uninsured to the insured ("ObamaCare and the Truth About 'Cost Shifting'," op-ed, March 11). It is not the insured who pay a price for the uninsured, it is the opposite.

T-Cell Immunotherapy: Researchers Predict Age of T Cells to Improve Cancer Treatment

3/3/2011 11:05 am

(Georgia Tech) Mar 2, 2011 - Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body’s own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and neuroblastoma.

Lance Armstrong Campaigns for Tobacco Tax Initiative to Fund Cancer Research

2/28/2011 12:00 am

(Los Angeles Times) Feb 27, 2011 - Seven-time Tour de France winner Lance Armstrong will launch a campaign in support of the California Cancer Research Act, which would add a $1 tax to tobacco products.

Study Indicates Cellphones Affect Brain Activity, But Implications Are Unclear

2/23/2011 12:00 am

(Washington Post) Feb 22, 2011 - Are cellphones safe? That question has gotten a lot of attention, but so far there has been no convincing evidence that those ubiquitous devices cause health problems. A new federal study may stir things up further, but the bottom line again is that the study raises more questions than it answers.

Urologist Reveals New Drug May Prolong Men's Survival with Hard-To-Treat Prostate Cancer

2/22/2011 12:00 am

(Frisco Texas News) Feb 20, 2011 - According to new findings, abiraterone acetate, an investigational drug, can prolong survival of men with metastatic castration-resistant prostate cancer (CRPC) whose disease is progressing after receiving docetaxel-based chemotherapy.

Study: Eating More Fiber Could Mean Longer Life

2/15/2011 12:00 am

(Washington Post) Feb 15, 0211 - Eat more fiber and you just may live longer. That's the message from the largest study of its kind to find a link between high-fiber diets and lower risks of death not only from heart disease, but from infectious and respiratory illnesses as well.